Industry Partners & Recognition
Mymee’s proprietary method of identifying an individual’s unique autoimmune disease & long COVID triggers has been validated in real world studies & peer-reviewed publications, demonstrating meaningful improvements in fatigue, brain fog, pain & other debilitating symptoms.
Research measured ten PROMIS® HRQoL domains, in addition to 59 types of patient reported symptoms.
Mymee is HIPAA-compliant and SOC-2 audited, and adheres to strict privacy standards to protect data.
Industry leaders support Mymee
"Mymee is a completely new treatment modality for autoimmune disease and as a clinician, that is fascinating. It is a great alternative in a field that has not evolved very much despite pharmacological advancements."
Kurt Herzer, MD, PhD, Former Head of Population Health, Oscar Health
"As part of our trusted performance network, Mymee has been a true innovation partner in working with our post COVID Recovery clinic to manage the care of as many people with long COVID as possible."
Dr. David Putrino, Director of Rehabilitation Innovation at Mount Sinai Hospital
"As an innovator in the healthcare industry, I know an effective product when see it. And as someone whose family member directly benefited from the Mymee program, I can attest to the fact that Mymee works."
John Bell, VP External Innovation & New Business Models, Johnson & Johnson